To summarize current knowledge of potential targets for boron transport in Boron Neutron Capture Therapy (BNCT) and their significance in improving treatment outcomes.
Key Findings:
BNCT is effective for various cancers, requiring tumor concentrations of boron ≥ 20 μg/g and specific T/N and T/B ratios, which are critical for treatment efficacy.
Only two boron carriers, sodium mercaptoundecahydrododecaborate-10B (BSH) and boronophenylalanine-10B (BPA), are clinically approved.
LAT1 is a key transporter for BPA, with expression levels correlating with tumor types and clinical outcomes, enhancing boron delivery.
Interpretation:
The review highlights the importance of LAT1 and other transport mechanisms in enhancing boron delivery for effective BNCT, suggesting avenues for targeted therapies.
Limitations:
The review primarily focuses on selective accumulation without addressing the subsequent neutron irradiation effects, which are crucial for treatment success.
Limited discussion on the clinical applicability of identified transport mechanisms and their potential impact on patient outcomes.
Conclusion:
Identifying and targeting specific transport mechanisms, such as LAT1, may improve the efficacy of BNCT in cancer treatment.
